SXLV:LSE:LSE-SPDR S&P U.S. Health Care Select Sector UCITS (USD)

ETF | Others |

Last Closing

USD 43.9738

Change

-0.37 (-0.82)%

Market Cap

N/A

Volume

2.99K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-02 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XNIF:LSE Xtrackers Nifty 50 Swap UCITS ..

-414.00 (-2.04%)

USD 292,109.69B
XNID:LSE Xtrackers Nifty 50 Swap UCITS ..

-2.54 (-0.97%)

USD 292,109.69B
0R1O:LSE Amazon.com Inc.

-12.20 (-6.34%)

USD 1,607.29B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

-0.62 (-3.49%)

USD 701.81B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

-0.64 (-4.67%)

USD 636.56B
0R1I:LSE NVIDIA Corp.

-6.49 (-5.96%)

USD 618.20B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
0QZK:LSE Coca-Cola Co.

+1.85 (+2.57%)

USD 266.08B
PRJU:LSE Amundi Index Solutions - Amund..

-1.02 (-3.41%)

USD 259.48B
0QZO:LSE 0QZO

-6.35 (-6.50%)

USD 258.54B

ETFs Containing SXLV:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.91% 78% C+ 72% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.91% 78% C+ 72% C
Trailing 12 Months  
Capital Gain 0.80% 35% F 46% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.80% 31% F 43% F
Trailing 5 Years  
Capital Gain 76.79% 59% D- 66% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 76.79% 56% F 64% D
Average Annual (5 Year Horizon)  
Capital Gain 9.97% 63% D 67% D+
Dividend Return 9.97% 62% D 66% D+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 10.09% 65% D 80% B-
Risk Adjusted Return 98.83% 87% B+ 93% A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike